Net profit of Ipca Laboratories rose 31.49% to Rs 326.27 crore in the quarter ended December 2025 as against Rs 248.14 crore during the previous quarter ended December 2024. Sales rose 6.55% to Rs 2392.50 crore in the quarter ended December 2025 as against Rs 2245.37 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales2392.502245.37 7 OPM %22.2920.62 - PBDT535.92466.38 15 PBT428.33367.92 16 NP326.27248.14 31 Powered by Capital Market - Live News

Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 13 February 2026.Powered by Capital Market - Live News

Net profit of Ipca Laboratories rose 23.13% to Rs 282.57 crore in the quarter ended September 2025 as against Rs 229.48 crore during the previous quarter ended September 2024. Sales rose 8.56% to Rs 2556.50 crore in the quarter ended September 2025 as against Rs 2354.90 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales2556.502354.90 9 OPM %21.3218.75 - PBDT553.17445.18 24 PBT449.84344.83 30 NP282.57229.48 23 Powered by Capital Market - Live News

Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live News

Ipca Laboratories has incorporated a wholly owned subsidiary by the name �Ipca Pharmaceuticals GmbH� in the Federal Republic of Germany, with an initial paid up capital of Euro � 25,000, inter-alia, to hold product registrations, participate in the institutional and other business and undertake distribution of generic formulations in the said country. Powered by Capital Market - Live News